PRDM9

Across TCGA pan-cancer cohorts, PRDM9 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated PRDM9 data layer compared with 19 for mass-spec protein.

The strongest signal is observed in uveal melanoma (UVM), where higher PRDM9 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PRDM9 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

UVM, SCLC, and UCEC are the cancer types where PRDM9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UVM	DFS	Median	All	0.032	0.762	<.001	30	view →
SCLC	OS	Median	IV	0.137	0.548	.004	12	view →
UCEC	DFS	Median	II,III,IV	0.854	0.431	.022	8	view →
DLBC	OS	Median	All	0.054	0.842	<.001	6	view →
LUSC	DFS	Median	III,IV	0.079	0.751	.024	6	view →
LUAD	DFS	Median	IV	0.342	0.893	<.001	6	view →
ACC	OS	Median	All	0.149	0.686	.047	3	view →
CESC	DFS	Median	All	0.520	0.745	.044	2	view →
SKCM	DFS	Median	All	0.773	0.614	.042	1	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

PRDM9–UVM (DFS)

Open the UVM breakdown →